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OBJECTIVES: Low persistence with antihypertensive drug treat-
ment (AHT) is expected to limit patient’s beneﬁts in terms of a
reduction of cardiovascular and cerebrovascular disease. This
study investigated the relationship between persistence with anti-
hypertensive drugs and the risk of stroke in clinical practice.
METHODS: From the PHARMO Record Linkage System com-
prising, among others, linked drug-dispensing and hospital
records of >2 million inhabitants in The Netherlands, new users
of AHT were identiﬁed in the period 1993–2002. Persistence
with AHT was determined by summing the number of days of
continuous treatment (gaps between dispensings of <60 days).
Patients were classiﬁed as persistent if they remained on AHT
for at least two years. The outcome of interest was the ﬁrst hos-
pital admission for stroke occurring two or more years after 
initiation of AHT therapy. Patients were classiﬁed as high, inter-
mediate or low cardiovascular risk based on other cardiovascu-
lar drug use and hospitalizations during the ﬁrst two years of
follow-up. RESULTS: The study included 98,485 patients of
whom 16% were at high cardiovascular risk. About 50% (n =
48,548) of all patients were persistent with AHT for two years,
and 2.1% (n = 2093) were hospitalized for stroke in the period
of two or more years after initiation of AHT therapy. Multi-
variate analyses showed that non-persistent users of AHT had a
16%–19% increased risk for stroke compared to persistent users
(Low/intermediate risk group RRadj = 1.19; 95% CI: 1.07–1.32;
high risk group RRadj = 1.16; 95% CI: 0.97–1.39). CONCLU-
SION: In clinical practice antihypertensive drug treatment is used
over too short a time interval to have maximum beneﬁt from
preventing stroke.
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OBJECTIVES: Low persistence with antihypertensive drug treat-
ment (AHT) may limit patient’s beneﬁts in terms of a reduction
of cardiovascular and cerebrovascular disease. This study in-
vestigated the relationship between persistence with antihy-
pertensive drugs and the risk of acute myocardial infarction
(AMI) in clinical practice. METHODS: From the PHARMO
record linkage system comprising, among others, linked drug-
dispensing and hospital records of >2 million inhabitants in The
Netherlands, new users of AHT were identiﬁed in the period
1993–2002. Persistence with AHT was determined by summing
the number of days of continuous treatment (gaps between dis-
pensings <60 days). Persistent patients remained on AHT for two
years. The outcome of interest was the ﬁrst hospital admission
for AMI occurring two or more years after initiation of AHT
therapy. Patients were classiﬁed as high, intermediate or low car-
diovascular risk based on other cardiovascular drug use and hos-
pitalizations during the ﬁrst two years of follow-up. RESULTS:
The study included 98,485 patients of whom 16% were at high
cardiovascular risk. About 50% of all patients were persistent
with AHT for two years and 1.5% was hospitalized for AMI in
the period of two or more years after initiation of AHT. Multi-
variate analyses showed that non-persistent use of AHT
increased the risk for AMI in the low/intermediate risk group
(RRadj = 1.12; 95% CI: 0.99–1.28), but not in the high risk
group (RRadj = 0.90; 95% CI: 0.73–1.10). CONCLUSION: In
clinical practice antihypertensive drug treatment is used over too
short a time interval to have maximum beneﬁt for preventing
AMI in patients with low or intermediate cardiovascular risk.
PCV7
RELATIONSHIPS BETWEEN VENOUS THROMBOEMBOLIC
(VTE) PROPHYLACTIC TREATMENTS AND VTE
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OBJECTIVES: To compare rates of venous thromboembolic
(VTE) complications and thrombocytopenia by VTE prophylac-
tic treatments, among Department of Veterans Affairs (VA)
patients receiving total hip replacement(THR). METHODS:
From the VA national databases, we identiﬁed all THR patients
between March 2003 and March 2004. Using inpatient and out-
patient data; we collected demographics, diagnoses, health care
utilization, and VTE prophylactic strategies for each patient. We
followed patients for 1 year post-surgery, applying diagnostic
codes to identify VTE complications (deep vein thrombosis
(DVT)), pulmonary embolism (PE), post-thrombotic syndrome
(PTS)), and thrombocytopenia. Using logistic regression; con-
trolling for age, gender, obesity, congestive heart failure, and
cancer; we compared VTE complications and thrombocytopenia
by VTE prophylaxis (reference = enoxaparin alone). RESULTS:
We found 1722 THRs with VTE prophylaxis: enoxaparin = 1005
(58.4%), warfarin = 345 (20.0%), dalteparin = 205 (11.9%), and
the combination of enoxaparin with warfarin (enox/warf) = 167
(9.7%). Respectively, patients experiencing VTE complications
(chi square p < 0.001) were: 26 (2.6%), 22 (6.4%), 5 (2.4%),
and 34 (20.4%) or suffering thrombocytopenia (chi square p =
0.177) were: 6 (0.5%), 3 (0.9%), 1 (0.5%), and 4 (2.4%). Logis-
tic regression revealed signiﬁcantly greater (p < 0.001) VTE com-
plications (odds ratio, 95% conﬁdence intervals) with enox/warf
(9.9, 5.6–17.2) or warfarin alone (2.6, 1.5–4.7) versus enoxa-
parin alone. Signiﬁcant covariates were age (p = 0.016) and cancer
diagnosis (p = 0.018). Treatment with enox/warf was associated
with signiﬁcantly (p < 0.001) more PEs, 4.8% versus 0.5% (10.6,
3.7–33.6). Treatment with enox/warf or warfarin alone was asso-
ciated with more (p < 0.001) DVTs, 17.4% versus 2.2% (9.4,
5.2–17.1) and 5.2% versus 2.2% (2.5, 1.3–4.8). There were no
cases of PTS. Logistic regression results for thrombocytopenia
were not signiﬁcant (p = 0.174). CONCLUSION: Warfarin and
enox/warf were signiﬁcantly less effective VTE prophylactic
strategies following THR than dalteparin or enoxaparin. Poten-
tial limitations include the non-controlled, observational design,
inclusion of primarily male VA patients, and constraints inherent
in national VA data.
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